Global Choroidal Neovascularization Market Overview:
Global Choroidal Neovascularization Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2026-2035, Considering the Base Year As 2025.
Global Choroidal Neovascularization Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of Choroidal Neovascularization involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Choroidal Neovascularization Market:
The Choroidal Neovascularization Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Choroidal Neovascularization Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Choroidal Neovascularization Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Choroidal Neovascularization market has been segmented into:
Anti-Angiogenic Therapy
Laser Photocoagulation
Photodynamic Therapy
Verteporfin Sodium
Ranibizumab
Bevacizumab
Aflibercept
Pegaptanib Sodium
By Application, Choroidal Neovascularization market has been segmented into:
Age-Related Macular Degeneration (AMD
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Choroidal Neovascularization market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Choroidal Neovascularization market.
Top Key Players Covered in Choroidal Neovascularization market are:
Regeneron Pharmaceuticals Inc
Oxurion NV
Iveric Bio Inc
Roche Holding AG
Janssen Pharmaceuticals Inc
Alcon Laboratories Inc
Genentech Inc
Carl Zeiss Meditec AG
Allergan
Santen Pharmaceutical Co. Ltd
Topcon Corporation
Teva Pharmaceutical Industries Ltd.
Apellis Pharmaceuticals Inc
Bayer AG
Novartis AG
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Choroidal Neovascularization Market Type
4.1 Choroidal Neovascularization Market Snapshot and Growth Engine
4.2 Choroidal Neovascularization Market Overview
4.3 Anti-Angiogenic Therapy
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Anti-Angiogenic Therapy: Geographic Segmentation Analysis
4.4 Laser Photocoagulation
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Laser Photocoagulation: Geographic Segmentation Analysis
4.5 Photodynamic Therapy
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.5.3 Photodynamic Therapy: Geographic Segmentation Analysis
4.6 Verteporfin Sodium
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.6.3 Verteporfin Sodium: Geographic Segmentation Analysis
4.7 Ranibizumab
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.7.3 Ranibizumab: Geographic Segmentation Analysis
4.8 Bevacizumab
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.8.3 Bevacizumab: Geographic Segmentation Analysis
4.9 Aflibercept
4.9.1 Introduction and Market Overview
4.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.9.3 Aflibercept: Geographic Segmentation Analysis
4.10 Pegaptanib Sodium
4.10.1 Introduction and Market Overview
4.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.10.3 Pegaptanib Sodium: Geographic Segmentation Analysis
Chapter 5: Choroidal Neovascularization Market Application
5.1 Choroidal Neovascularization Market Snapshot and Growth Engine
5.2 Choroidal Neovascularization Market Overview
5.3 Age-Related Macular Degeneration (AMD
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Age-Related Macular Degeneration (AMD: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Choroidal Neovascularization Market Share by Manufacturer (2023)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 REGENERON PHARMACEUTICALS INC
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 OXURION NV
6.4 IVERIC BIO INC
6.5 ROCHE HOLDING AG
6.6 JANSSEN PHARMACEUTICALS INC
6.7 ALCON LABORATORIES INC
6.8 GENENTECH INC
6.9 CARL ZEISS MEDITEC AG
6.10 ALLERGAN
6.11 SANTEN PHARMACEUTICAL CO. LTD
6.12 TOPCON CORPORATION
6.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.
6.14 APELLIS PHARMACEUTICALS INC
6.15 BAYER AG
6.16 NOVARTIS AG
Chapter 7: Global Choroidal Neovascularization Market By Region
7.1 Overview
7.2. North America Choroidal Neovascularization Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Anti-Angiogenic Therapy
7.2.2.2 Laser Photocoagulation
7.2.2.3 Photodynamic Therapy
7.2.2.4 Verteporfin Sodium
7.2.2.5 Ranibizumab
7.2.2.6 Bevacizumab
7.2.2.7 Aflibercept
7.2.2.8 Pegaptanib Sodium
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Age-Related Macular Degeneration (AMD
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Choroidal Neovascularization Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Anti-Angiogenic Therapy
7.3.2.2 Laser Photocoagulation
7.3.2.3 Photodynamic Therapy
7.3.2.4 Verteporfin Sodium
7.3.2.5 Ranibizumab
7.3.2.6 Bevacizumab
7.3.2.7 Aflibercept
7.3.2.8 Pegaptanib Sodium
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Age-Related Macular Degeneration (AMD
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Choroidal Neovascularization Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Anti-Angiogenic Therapy
7.4.2.2 Laser Photocoagulation
7.4.2.3 Photodynamic Therapy
7.4.2.4 Verteporfin Sodium
7.4.2.5 Ranibizumab
7.4.2.6 Bevacizumab
7.4.2.7 Aflibercept
7.4.2.8 Pegaptanib Sodium
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Age-Related Macular Degeneration (AMD
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Choroidal Neovascularization Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Anti-Angiogenic Therapy
7.5.2.2 Laser Photocoagulation
7.5.2.3 Photodynamic Therapy
7.5.2.4 Verteporfin Sodium
7.5.2.5 Ranibizumab
7.5.2.6 Bevacizumab
7.5.2.7 Aflibercept
7.5.2.8 Pegaptanib Sodium
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Age-Related Macular Degeneration (AMD
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Choroidal Neovascularization Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Anti-Angiogenic Therapy
7.6.2.2 Laser Photocoagulation
7.6.2.3 Photodynamic Therapy
7.6.2.4 Verteporfin Sodium
7.6.2.5 Ranibizumab
7.6.2.6 Bevacizumab
7.6.2.7 Aflibercept
7.6.2.8 Pegaptanib Sodium
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Age-Related Macular Degeneration (AMD
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Choroidal Neovascularization Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Anti-Angiogenic Therapy
7.7.2.2 Laser Photocoagulation
7.7.2.3 Photodynamic Therapy
7.7.2.4 Verteporfin Sodium
7.7.2.5 Ranibizumab
7.7.2.6 Bevacizumab
7.7.2.7 Aflibercept
7.7.2.8 Pegaptanib Sodium
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Age-Related Macular Degeneration (AMD
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Choroidal Neovascularization Scope:
|
Report Data
|
Choroidal Neovascularization Market
|
|
Choroidal Neovascularization Market Size in 2025
|
USD XX million
|
|
Choroidal Neovascularization CAGR 2025 - 2032
|
XX%
|
|
Choroidal Neovascularization Base Year
|
2024
|
|
Choroidal Neovascularization Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Regeneron Pharmaceuticals Inc, Oxurion NV, Iveric Bio Inc, Roche Holding AG, Janssen Pharmaceuticals Inc, Alcon Laboratories Inc, Genentech Inc, Carl Zeiss Meditec AG, Allergan, Santen Pharmaceutical Co. Ltd, Topcon Corporation, Teva Pharmaceutical Industries Ltd., Apellis Pharmaceuticals Inc, Bayer AG, Novartis AG.
|
|
Key Segments
|
By Type
Anti-Angiogenic Therapy
Laser Photocoagulation
Photodynamic Therapy
Verteporfin Sodium
Ranibizumab
Bevacizumab
Aflibercept
Pegaptanib Sodium
By Applications
Age-Related Macular Degeneration (AMD
|
